106 results
8-K
EX-99.2
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
8 Jan 24
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
6:05am
assessment provided evidence of favorable T - cell response in patients dosed with CNP - 104 Expect topline data from Phase 2 study in Q3 2024
20 Financial … = parenteral support; 3 MB = metabolic balance assessment 24
Mean ± 95% Confidence Interval Baseline4W 8W 12W 16W 20W 24W 28W 32W 36W 40W 44W 48W 52W
S-3ASR
IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares
9 Nov 23
Automatic shelf registration
4:07pm
in the registration statement. Our financial statements and our management’s assessment of the effectiveness of internal control over financial reporting
8-K/A
EX-99.1
xdltlar08d8mi
11 Sep 23
Index to Financial Statements
4:30pm
SC TO-T
EX-99
exm j2d3eoekot
31 May 23
Third party tender offer statement
6:46am
SC TO-C
EX-10.1
7z2tyiihvpfgppszh9s
22 May 23
Information about tender offer
4:26pm
SC TO-C
EX-2.1
7si 05cjcg
22 May 23
Information about tender offer
4:26pm
8-K
EX-2.1
65e75
22 May 23
Entry into a Material Definitive Agreement
4:25pm
8-K
EX-10.1
h1lboba5 ak3qor
22 May 23
Entry into a Material Definitive Agreement
4:25pm